Skip to main content
Clinical Trials/NCT01364480
NCT01364480TerminatedNot Applicable

Microelectrode Brain-Machine Interface for Individuals With Tetraplegia

Michael Boninger2 sites in 1 country1 target enrollmentStarted: May 1, 2011Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Terminated
Sponsor
Enrollment
1
Locations
2
Primary Endpoint
Number of Participants With Successful Implant

Study Overview

Brief Summary

The purpose of this research study is to demonstrate the safety and efficacy of using two NeuroPort Arrays (electrodes) for long-term recording of brain activity.

Detailed Description

Individuals with tetraplegia (paralysis caused by illness or injury that results in partial or total loss of use of the arms and legs) have intact brain function but are unable to move due to injury or disease affecting the spinal cord, nerves or muscles. Brain-machine interface (BMI) technology is based on the finding that with intact brain function, neural signals are generated even though they are not sent to the arms, hands and legs. By implanting electrodes in the brain, individuals can be trained to send neural signals which are interpreted by a computer and translated to movement which can then be used to control a variety of devices or computer displays.

Study Design

Study Type
Interventional
Allocation
Na
Intervention Model
Single Group
Primary Purpose
Other
Masking
None

Eligibility Criteria

Ages
18 Years to 70 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Limited or no ability to use both hands due to cervical spinal cord injury or brainstem or spinal stroke
  • At least 1 year post-injury
  • Live within 1 hour of the University of Pittsburgh and be willing to travel to the University of Pittsburgh once per week for BMI training
  • Additional inclusion criteria must also be reviewed

Exclusion Criteria

  • Certain implanted devices
  • Presence of other serious disease or disorder that could affect ability to participate in this study
  • Individuals who are immunosuppressed or who have conditions that typically result in immunocompromise
  • Additional exclusion criteria must also be reviewed

Outcomes

Primary Outcomes

Number of Participants With Successful Implant

Time Frame: One year following array implantation

Number of participants who were implanted for at least one year without having to explant the device for safety reasons.

Secondary Outcomes

  • 7 Degree-of-freedom Movement by Neural Control(One year following array implantation)
  • 10 Degree-of-freedom Movement by Neural Control(One year following array implantation)

Investigators

Sponsor
Michael Boninger
Sponsor Class
Other
Responsible Party
Sponsor Investigator
Principal Investigator

Michael Boninger

Vice Chair of Research

University of Pittsburgh

Study Sites (2)

Loading locations...

Similar Trials